Calcitonin	calcitonin	CHEMICALS	O	OTHERS	I
gene-related	gene-related	O	O	O	O
peptide	peptide	O	O	O	O
levels	levels	O	O	O	O
during	during	O	O	O	O
nitric	nitric	O	O	O	O
oxide-induced	oxide-induced	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	O	O	O
tension-type	tension-type	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
.	.	O	O	O	O

It	it	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
proposed	proposed	O	O	O	O
that	that	O	O	O	O
nitric	nitric	CHEMICALS	O	OTHERS	I
oxide	oxide	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
NO	no	O	O	O	O
)	)	O	O	O	O
induced	induced	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
in	in	O	O	O	O
primary	primary	O	O	OTHERS	I
headaches	headaches	O	O	OTHERS	I
may	may	O	O	O	O
be	be	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
release	release	O	O	O	O
of	of	O	O	O	O
calcitonin	calcitonin	CHEMICALS	O	OTHERS	I
gene-related	gene-related	O	O	O	O
peptide	peptide	O	O	O	O
(	(	O	O	O	O
CGRP	cgrp	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
we	we	O	O	O	O
aimed	aimed	O	O	O	O
to	to	O	O	O	O
investigate	investigate	O	O	O	O
plasma	plasma	O	O	O	O
levels	levels	O	O	O	O
of	of	O	O	O	O
CGRP	cgrp	CHEMICALS	O	OTHERS	I
during	during	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
NO	no	O	O	O	O
donor	donor	O	O	O	O
glyceryl	glyceryl	O	O	OTHERS	I
trinitrate	trinitrate	O	O	OTHERS	I
(	(	O	O	O	O
GTN	gtn	O	O	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
16	16	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
chronic	chronic	O	O	O	O
tension-type	tension-type	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
and	and	O	O	O	O
16	16	O	O	O	O
healthy	healthy	O	O	O	O
controls	controls	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
subjects	subjects	O	O	O	O
were	were	O	O	O	O
randomly	randomly	O	O	O	O
allocated	allocated	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
0.5	0.5	O	O	O	O
microg/kg/min	microg/kg/min	O	O	O	O
GTN	gtn	O	O	OTHERS	I
or	or	O	O	O	O
placebo	placebo	O	O	O	O
over	over	O	O	O	O
20	20	O	O	O	O
min	min	O	O	O	O
on	on	O	O	O	O
two	two	O	O	O	O
headache-free	headache-free	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

Blood	blood	O	O	O	O
samples	samples	O	O	O	O
were	were	O	O	O	O
collected	collected	O	O	O	O
at	at	O	O	O	O
baseline	baseline	O	O	O	O
,	,	O	O	O	O
10	10	O	O	O	O
,	,	O	O	O	O
20	20	O	O	O	O
and	and	O	O	O	O
60	60	O	O	O	O
min	min	O	O	O	O
after	after	O	O	O	O
start	start	O	O	O	O
of	of	O	O	O	O
infusion	infusion	O	O	O	O
.	.	O	O	O	O

Both	both	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
controls	controls	O	O	O	O
developed	developed	O	O	O	O
significantly	significantly	O	O	O	O
stronger	stronger	O	O	O	O
immediate	immediate	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
on	on	O	O	O	O
the	the	O	O	O	O
GTN	gtn	O	O	OTHERS	I
day	day	O	O	O	O
than	than	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
day	day	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
was	was	O	O	O	O
significantly	significantly	O	O	O	O
more	more	O	O	O	O
pronounced	pronounced	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
than	than	O	O	O	O
in	in	O	O	O	O
controls	controls	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
was	was	O	O	O	O
no	no	O	O	O	O
difference	difference	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
area	area	O	O	O	O
under	under	O	O	O	O
the	the	O	O	O	O
CGRP	cgrp	CHEMICALS	O	OTHERS	I
curve	curve	O	O	O	O
(	(	O	O	O	O
AUCCGRP	auccgrp	O	O	O	O
)	)	O	O	O	O
on	on	O	O	O	O
GTN	gtn	O	O	OTHERS	I
vs.	vs.	O	O	O	O
placebo	placebo	O	O	O	O
day	day	O	O	O	O
in	in	O	O	O	O
either	either	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
P=0.65	p=0.65	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
controls	controls	O	O	O	O
(	(	O	O	O	O
P=0.48	p=0.48	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
AUCCGRP	auccgrp	O	O	O	O
recorded	recorded	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
GTN	gtn	O	O	OTHERS	I
day	day	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
differ	differ	O	O	O	O
between	between	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
controls	controls	O	O	O	O
(	(	O	O	O	O
P=0.36	p=0.36	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Both	both	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
controls	controls	O	O	O	O
,	,	O	O	O	O
CGRP	cgrp	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
changed	changed	O	O	O	O
significantly	significantly	O	O	O	O
over	over	O	O	O	O
time	time	O	O	O	O
,	,	O	O	O	O
on	on	O	O	O	O
both	both	O	O	O	O
the	the	O	O	O	O
GTN	gtn	O	O	OTHERS	I
and	and	O	O	O	O
placebo	placebo	O	O	O	O
days	days	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
indicates	indicates	O	O	O	O
that	that	O	O	O	O
NO-induced	no-induced	O	O	O	O
immediate	immediate	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
is	is	O	O	O	O
not	not	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
release	release	O	O	O	O
of	of	O	O	O	O
CGRP	cgrp	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

